— PSI-938 achieves a median 3.94 to 4.64 log10 reduction in HCV RNA after 7 days of monotherapy
— No early discontinuations or serious adverse events reported
— Initiating nucleotide combination trial later this quarter
— Conference call at 8:00 AM ET today
PRINCETON, N.J., Oct. 28 /PRNewswire-FirstCall/ — Pharmasset, Inc. (Nasdaq: VRUS) reported positive preliminary results today from its phase I monotherapy trial of PSI-352938 (“PSI-938”) for the treatment of chronic hepatitis C (HCV). PSI-938 is a guanosine nucleotide analog polymerase inhibitor in development for the treatment of chronic HCV infection.